Associate Professor of Public Law
Editor Biobank Perspectives
Anna-Sara Lind joined CRB in September 2011 to work with the legal aspects of research conducted on human tissue samples within BBMRI.se and BBMRI-LPC. Anna-Sara Lind is Associate Professor of Public Law and Senior Lecturer at the Department of Law at Uppsala University and is tied part-time to CRB.
She is editor of our newsletter Biobank Perspectives: Current issues in ethics and law.
Phone: +46 18 471 61 99
Recently in the media
- Öppenheten förstör chansen till patent
Svenska Dagbladet, debatt, 2015-06-21
Stem cell treatment of type 1 diabetes
We provide ethical and legal analysis and guidance on development of products for treating type 1 diabetes, using cells derived from human embryonic stem cells.
ELSI-Service for BBMRI.se
We run the ELSI-Services for BBMRI.se (BioBanking and Molecular Resource Infrastructure of Sweden): a national effort for efficient and automated collection of biological material funded by the Swedish Research Council.
- Socialrätt under omvandling, Stockholm: Liber förlag. ss. 344-356
- Socialrätt under omvandling, Stockholm: Liber förlag. ss. 10-16
- Transparency in the Future, Visby: Ragulka förlag. ss. 51-64
- Mänskliga rättigheter i det offentliga Sverige, Lund: Studentlitteratur AB. ss. 99-116
- Mänskliga rättigheter i det offentliga Sverige, Lund: Studentlitteratur. ss. 15-20
- Visby: Ragulka förlag.
- Transparency in the future, . ss. 9-17
Biobank and registry ethics & law
For many years, researchers at CRB have provided constructive advise on how to deal with ethical and legal aspects of research using human tissue material and personal data. We have collaborated with biomedical scientists and published our findings in peer reviewed journals. As a summary of this research we have compiled a list of publications with abstracts. We have grouped them thematically to help you find the ones you might be interested in reading. Our publications deal with ethical frameworks and policy, regulatory aspects of biobank and registry research, informed consent, ethical review, integrity concerns, trust, genetic testing, indicental findings, commercialization, public and patient perceptions, rare diseases, children & biobanks & genetics, and biobank studies.